Is "seronegative" MG explained by autoantibodies to MuSK?

Neurology

Volumn 62, Issue 11, 2004, Pages 1920-1921

  Lindstrom, Jon ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA BUNGAROTOXIN; BINDING PROTEIN; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; MUSCLE SPECIFIC RECEPTOR TYROSINE KINASE; NICOTINIC RECEPTOR; PROTEIN TYROSINE KINASE; UNCLASSIFIED DRUG;

ANTIBODY DETECTION; ANTIBODY PRODUCTION; ANTIGEN BINDING; CROSS LINKING; EDITORIAL; ELECTRON MICROSCOPY; ELECTROPHYSIOLOGY; GENE MUTATION; HUMAN; MEDICAL RESEARCH; MUSCLE WEAKNESS; MYASTHENIA GRAVIS; NEUROMUSCULAR TRANSMISSION; PATHOPHYSIOLOGY; POSTSYNAPTIC MEMBRANE; PRIORITY JOURNAL; PROTEIN DEGRADATION; SYNAPTOGENESIS;

EID: 2942532978     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.WNL.0000129702.41868.A5     Document Type: Editorial

References (15)

1. Lindstrom J. Acetylcholine receptors and myasthenia. Muscle Nerve 2000;23:453-477.
2. Hoch W, McConville J, Helms S, Newsom-Davis J, Melms A, Vincent A. Autoantibodies to the receptor kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nat Med 2001;7: 365-368.
3. Sanders D, Salem K, Massey J, McConville J, Vincent A. Clinical aspects of MuSK antibody positive seronegative MG. Neurology 2003;60: 1978-1980.
4. Liyanagi Y, Hoch W, Beeson D, Vincent A. The agrin/muscle specific kinase pathway: new targets for autoimmune and genetic disorders at the neuromuscular junction. Muscle Nerve 2002;25:4-16.
5. Mossman S, Vincent A, Newsom-Davis J. Myasthenia gravis without acetylcholine receptor antibody: a distinct disease entity. Lancet 1986; 1:116-118.
6. Burges J, Vincent A, Molenaar P, Newsom-Davis J, Peers C, Wray D. Passive transfer of seronegative myasthenia gravis to mice. Muscle Nerve 1994;17:1391-1400.
7. Blaes F, Beeson D, Plested P, Lang B, Vincent A. IgG from "seronegative" myasthenia gravis patients binds to a muscle cell line, TE671, but not to human acetylcholine receptor. Ann Neurol 2000;47:504-510.
8. Vincent A, McConville J, Farrugia M, et al. Antibodies in myasthenia gravis and related disorders. Ann NY Acad Sci 2003;998:324-335.
9. Lu C, Lu L, Hao Z-S, Xia D-G, Qain J, Arnason B. Antibody-secreting cells to acetylcholine receptor and presynaptic membrane receptor in seronegative myasthenia gravis. J Neuroimmunol 1993;43:145-150.
10. Yeh J-H, Chen W-H, Chiu H-C, Vincent A. Low frequency of MuSK antibody in generalized seronegative myasthenia gravis among Chinese. Neurology 2004;62:2131-2132.
11. Ohta K, Shigemoto K, Kubo S, et al. MuSK antibodies in AChR Abseropositive MG vs. AChR Ab-seronegative MG. Neurology 2004;62: 2132-2133.
12. Selcen D, Fukuda T, Shen X-M, Engel A. Are MuSK antibodies the primary cause of myasthenic symptoms? Neurology 2004;62:1945-1950.
13. Matsuki K, Jiyi T, Tokunaga K, et al. HLA antigens in Japanese patients with myasthenia gravis. J Clin Invest 1990;86:392-399.
14. Dechiara T, Bowen D, Valenzuela D, et al. The receptor tyrosine kinase MuSK is required for neuromuscuIar junction formation in vivo. Cell 1996;85:501-512.
15. Engel A, Ohno K, Sine S. Sleuthing molecular targets for neurological diseases at the neuromuscular junction. Nat Rev Neurosci 2003;4:339-352.